To explore the incidence and risk factors for treatmentrelated acute esophagitis associated with involved-field radiation therapy (RT) delivered concurrently with chemotherapy for patients with locoregionally advanced non-small cell lung cancer.
T reatment-related esophagitis is a common complication of the treatment of lung cancer. Most patients who undergo thoracic radiation therapy (RT) for non-small cell lung cancer (NSCLC) develop acute esophagitis. 1 Severe esophagitis can necessitate hospitalization, initiation of percutaneous or parenteral feeding, and treatment interruption. These complications significantly affect quality of life and can negatively impact long-term survival. 2 The objective of the present retrospective study was to explore the incidence and the risk factors for treatment-related acute esophagitis associated with involved-field RT delivered concurrently with platinum-based chemotherapy for patients with locoregionally advanced NSCLC.
MATERIALS AND METHODS

Study Subjects
The study sample is represented by 49 consecutive patients diagnosed with clinical American Joint Committee of Cancer stage IIIA and IIIB NSCLC, treated with involved-field RT concurrently with platinum-based chemotherapy, at the Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, between October 2006 and February 2011. Twenty-seven patients (55%) were diagnosed with clinical stage IIIA disease and 22 patients (45%) with stage IIIB disease. Approval was granted by the Institutional Review Board for conducting this study. Patient characteristics are presented in Table 1 .
Radiotherapy
All 49 patients in this series were treated using involvedfield RT. Radiotherapy target volumes included the primary lung tumor and involved mediastinal lymphadenopathy as defined on imaging studies including computed tomography (CT) of the chest and [18F] fluorodeoxyglucose-positron emission tomography/CT. Three-dimensional conformal RT (3DCRT) plans were generated for 48 patients. Intensitymodulated RT (IMRT) was used for the treatment of 1 patient in this study cohort. The patients were treated to a median total dose of 63 Gy (range, 55.8 to 74 Gy) using daily fractions of 1.8 or 2.0 Gy, 5 d/wk. Twenty-five patients (51%) were treated using a 1.8 Gy dose per fraction, and 24 patients (49%) were treated using 2.0 Gy per fraction. No elective radiotherapy of mediastinal lymph nodes was used.
All patients underwent a CT-based simulation scan using 3-mm-thick slices to cover the entire thoracic area from which 3DCRT and/or IMRT plans were generated. Oral contrast was used immediately before scanning the patients to accurately outline the esophageal contour. The coverage of the target volumes and the dose to the esophagus were compared using the resulting dose volume histograms. The following esophageal dose parameters were identified and analyzed: mean and maximum esophageal doses, total esophageal volume, V35, V40, V55, V65, and V70, where volume variable (Vx) represents the percentage of the volume of the esophagus receiving Zx dose. The entire length of the esophagus was identified (from the crycoid cartilage to the gastroesophageal junction) and the entire esophageal volume was drawn.
Chemotherapy
Platinum-based chemotherapy was administered to all patients concurrently with radiotherapy. All patients were treated with weekly platinum-based chemotherapy. The regimens of chemotherapy included carboplatin and paclitaxel, cisplatin and etoposide, and cisplatin and pemetrexed.
Treatment-related Esophagitis Evaluation
Treatment-related toxicity was evaluated during the course of RT on weekly bases and subsequent follow-up visits. "Esophagitis" is defined in version 4.0 of National Cancer Institute's Common Terminology Criteria for Adverse Events (v4.0, CTCAE scale) as a disorder characterized by inflammation of the esophageal wall and its grading is based nearly entirely on symptoms, altered diet, and need for intervention ( Table 2) . No prophylactic medication was used to reduce the risk of esophagitis in this cohort.
Statistical Analysis
Patients and treatment characteristics of the study sample were summarized by descriptive statistics. The primary endpoint for data analysis is acute treatment-related esophagitis. Rates of grade 2 or higher esophagitis were summarized by week. A mixed-effects logistic regression model as implemented in SAS Proc Glimmix was used for model association of esophagitis with clinical and demographic characteristics while accounting for correlation among repeated measurements from the individual. As there was a clear increase in incidence of esophagitis over time, all models included week as a fixed effect. A random intercept was included to allow subject-specific deviations from the overall average risk. Separate models were fit to determine the association of each characteristic with each outcome, adjusted for week. Variables with marginal association (P < 0.25) were considered for inclusion in a multivariable model. Main effects were included in an initial model. Backwards elimination was used to remove nonsignificant terms (P > 0. 20) . No adjustments were made for multiple comparisons. SAS version 9.2 was used for all analysis.
RESULTS
Acute Treatment-related Esophagitis
Thirty-one patients (63%) developed treatment-related acute esophagitis: 24 patients (49%) with grade 2 esophagitis and 7 (14%) with grade 3 esophagitis, with the peak occurring during the seventh week of radiotherapy ( Fig. 1 ). Only 2 of 7 patients developing grade 3 acute esophagitis required hospitalization for severe dehydration. The other 5 patients with documented grade 3 acute esophagitis received intravenous fluids as outpatients at the medical oncology daycare unit. None of the patients without documented esophagitis used pain medication. Patients who developed grade 2 esophagitis were started on magic mouth wash (viscous lidocaine 2%, Maalox, diphenhydramine 1:1:1). For higher grade of esophagitis, morphine derivates were used for pain control. All these patients finished their RT course with only 2 patients having a treatment break of >2 days.
No grade Z4 esophagitis was seen in this cohort. Eighteen patients (37%) did not develop treatment-related esophagitis during their course of chemoradiotherapy. Thirtyeight of 39 patients were free from treatment-related esophagitis at 1 month after radiotherapy. One patient reported symptoms of grade 2 esophagitis at 1 month follow-up visit; Table 3 shows the association of patient and treatment characteristics with both outcomes adjusted for the increasing trend over time. In this univariate analysis, age at the time of diagnosis, radiation dose per fraction, and total volume of the esophagus were significantly associated with risk of acute esophagitis. Increasing age reduced risk of acute esophagitis (odds ratio [OR] for 10-y increase = 0.40) as did increasing total esophagus volume (OR for 10-U increase = 0.27). Dose per fraction of 1.8 Gy was associated with lower risk of acute esophagitis when compared with dose per fraction of 2 Gy (OR = 0.19) (Fig. 2) . The risk of acute esophagitis was marginally associated with dosimetrical parameters V35, V40, V55, V65, and V70 in the present study. The data regarding the volume (mL) of the treated esophagus and the maximum esophageal dose was also analyzed, but no correlation was found between these parameters and the risk of esophagitis.
Univariate Analysis
Multivariate Analysis
Results of the final multivariable models are given in Table 4 . Of the potential risk factors associated with acute treatment-related esophagitis selected for this final analysis, total esophagus volume and the radiation dose per fraction remained significantly associated with the risk of developing grade Z2 acute esophagitis. The risk of developing grade Z2 acute esophagitis over time was higher for patients with lower total volume (P = 0.003) and for the patients treated with larger dose per fraction (2 vs. 1.8 Gy) (P = 0.01).
DISCUSSION
The current standard of care for locoregionally advanced NSCLC is daily radiotherapy given with concurrent and frequent platinum-based chemotherapy. 3 The majority of the patients who undergo chemoradiotherapy for NSCLC develop acute esophagitis. 1 Newer treatment techniques such as 3DCRT and IMRT allow radiation oncologists to limit the dose of RT to the organ at risks such as esophagus when treating thoracic tumors. Moreover, involved-field RT is a radiation treatment technique that minimizes the radiation dose to uninvolved areas, including the organ at risks. All patients in this study were treated using involved-field 3DCRT or IMRT techniques and the associated incidence of grade Z3 acute esophagitis was 14%. Similar data have been reported that demonstrated a 17% rate of grade Z3 acute esophagitis for patients with NSCLC treated with definitive involved-field RT delivered concurrently with systemic chemotherapy. 4 Different risk factors for the development of acute esophagitis have been described in the literature, including the age at the time of diagnosis, preradiotherapy existent dysphagia, nodal stage of ZN2, twice-daily RT, and the use of concurrent chemotherapy. 1, [5] [6] [7] Our study suggested that increasing age reduces the risk of acute esophagitis (OR for 10-y increase = 0.40). The younger patients' age at the time of diagnosis (P = 0.018) was significantly associated with higher risk of developing acute esophagitis in univariate analysis but did not remain significant in multivariate analysis. We failed to identify an association between the nodal stage and the risk of acute esophagitis. A statistically significant association between the risk of esophagitis and the total volume of the esophagus has been demonstrated in the present study. Controversial data exist regarding the association between the length of esophagus included into the RT fields and the risk of esophagitis, 3,8-10 but to our knowledge, no data has been previously reported regarding the correlation between the total volume of the esophagus and the risk of esophagitis. Our study also demonstrated a higher risk of developing acute esophagitis associated with a larger radiation dose per fraction (2 vs. 1.8 Gy) (P = 0.01). The current data suggest that the use of a lower radiation dose per fraction (1.8 Gy) should be used to reduce the treatment-related esophagitis.
Numerous investigators have correlated esophageal toxicity with dose-volumetric data for patients who were treated with 3DCRT or IMRT. 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The risk of acute esophagitis was marginally associated with dosimetrical parameters V35, V40, V55, V65, and V70 in the present study. The lack of significant association between the risk of esophagiits and the esophageal Vx values may be related to the limited number of patients included into the present analysis. Our results are in accordance with previously published data showing the correlation between the 3D dose-volume histograms data and the treatment-related esophagitis. Quantitative Analysis of Normal Tissue Effects in the Clinic group recently demonstrated that some risk of acute esophagitis is present at intermediate doses of 30 to 50 Gy of thoracic RT and that the incidence of esophagitis increases with greater RT doses. Dose-volume histogram parameters describing cumulative dose higher than 50 Gy have been identified as highly statistically significantly correlated with acute esophagitis. 22 
CONCLUSIONS
Considering the limitations of this retrospective study, the present data suggest a higher risk of acute esophagitis associated with the age at the time of diagnosis, radiotherapy dose per fraction, and total esophagus volume. Further studies are necessary to validate these results. 
